• Recombinant Human Growth Hormone in IGF-1 Pathway Research

  2026-04-30

  Unlock reproducible IGF-1 pathway interrogation with APExBIO’s Recombinant Human Growth Hormone (GH), validated for high-potency cell signaling studies. This guide distills advanced workflows, troubleshooting strategies, and unique mechanistic insights for bone growth and chondrocyte biology models.

• Biomimetic Nanoparticles Mitigate Ovarian Inflammation via N

  2026-04-30

  This study introduces a biomimetic nanoparticle system for targeted delivery of α-cyperone to granulosa cells, effectively reducing LPS-induced inflammation and oxidative stress through Nrf2/HO-1 pathway activation. The approach offers a significant advance in potential therapies for diminished ovarian reserve, highlighting the synergistic role of nanotechnology and molecular targeting in reproductive medicine.

• Mubritinib (TAK 165): Rethinking OXPHOS in Virus-Driven Canc

  2026-04-29

  This thought-leadership article explores Mubritinib (TAK 165) as a transformative tool for translational researchers, highlighting its unique mechanism as a mitochondrial complex I inhibitor with selectivity for chemotherapy-resistant AML and KSHV-driven primary effusion lymphoma (PEL). By integrating mechanistic insights, experimental best practices, and strategic perspectives, we provide a roadmap for leveraging Mubritinib in advanced oncology and virology research. The article critically analyzes recent findings, protocol optimizations, and the evolving competitive landscape, offering actionable guidance and a forward-looking outlook for translational applications.

• Antibacterial Use and Resistance in Psychiatric Hospitals Du

  2026-04-29

  This study provides a detailed analysis of antibacterial drug use and evolving bacterial resistance patterns in a psychiatric hospital during the COVID-19 epidemic. By rigorously comparing local data with provincial and national figures, the research highlights the unique challenges psychiatric institutions face in balancing infection control and antimicrobial stewardship.

• Morin Inhibits AMPD2 to Restore Podocyte Mitochondrial Funct

  2026-04-28

  This study demonstrates that Morin, a natural flavonoid (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one), counteracts fructose-induced podocyte injury by inhibiting adenosine 5′-monophosphate deaminase (AMPD) activity, particularly AMPD2. These findings clarify Morin's mechanistic role in mitochondrial energy metabolism and its relevance for diabetic nephropathy models.

• EZ Cap Cy5 Firefly Luciferase mRNA: Dual-Mode Assay Power

  2026-04-28

  EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) delivers unmatched dual-modality detection for real-time tracking and quantification in mRNA delivery and expression studies. Its Cap1 capping, 5-moUTP modification, and Cy5 fluorescent labeling streamline advanced workflows, suppress innate immune activation, and yield robust, reproducible data across imaging and reporter assays.

• Structural Basis of HCAR3 Agonist Selectivity in Lipid Metab

  2026-04-27

  The reference study provides high-resolution cryo-EM structures of HCAR3 in complex with selective agonists, including (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (Acifran). These insights clarify the molecular determinants of ligand recognition and selectivity, informing next-generation hypolipidemic agent design with reduced side effects.

• Morin: Bioactive Flavonoid for Mitochondrial and Probe Appli

  2026-04-27

  Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one) is a high-purity flavonoid used in biomedical research for its antioxidant, anti-inflammatory, and fluorescent chelation properties. Its unique ability to inhibit adenosine 5′-monophosphate deaminase and act as an aluminum ion probe supports disease modeling in diabetes, neurodegeneration, and more.

• DiI (DiIC18(3)) Plasma Membrane Orange Fluorescent Probe: Pr

  2026-04-26

  DiI (DiIC18(3)) enables robust, high-contrast plasma membrane labeling in live and fixed cells, supporting applications like neuronal tracing and cell migration assays. This probe should not be used in water-based protocols or for targeting intracellular organelles. Researchers benefit most when requiring detailed membrane visualization with organic-solvent workflows.

• Peptidisc-Driven Nanobody Multimers: Enabling New Protein As

  2026-04-25

  This study introduces a peptidisc-assisted strategy to cluster nanobodies into multimeric and multispecific assemblies, termed polybodies, enhancing their affinity and functional versatility. The approach leverages hydrophobic clustering stabilized by peptidisc membrane mimetics and demonstrates potential for expanding protein engineering capabilities in biochemical research.

• Sulfo-NHS-SS-Biotin: Precision Protein Labeling for Affinity

  2026-04-24

  Sulfo-NHS-SS-Biotin empowers selective, reversible protein labeling, making it an indispensable tool for affinity purification and bioconjugation of cell surface proteins. Its cleavable disulfide linker and high aqueous solubility streamline workflows for cell biology and proteomics, as validated by both recent literature and robust product data.

• Improving In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-24

  Schwartz's dissertation reveals significant differences between relative and fractional viability metrics in in vitro drug response assays, highlighting how these measures capture distinct aspects of cancer cell fate. This work provides a framework to better interpret anti-cancer drug efficacy and suggests that more nuanced evaluation methods can refine preclinical testing and translational research.

• Cy5-UTP for RNA Labeling: Applied Workflows & Troubleshootin

  2026-04-23

  Cy5-UTP (Cyanine 5-UTP) empowers researchers with direct, sensitive fluorescent RNA labeling in complex workflows. Discover optimized in vitro protocols, troubleshooting strategies, and how lipid nanoparticle innovations inform next-generation probe design.

• Moxifloxacin: Fluoroquinolone Antibiotic for Cellular Toxici

  2026-04-23

  Moxifloxacin stands out as a broad-spectrum fluoroquinolone antibiotic, enabling precise exploration of DNA replication inhibition, cytotoxicity, and metabolic shifts in mammalian and bacterial cells. This guide details actionable experimental workflows, troubleshooting strategies, and differentiating insights—anchored by recent mechanistic advances and APExBIO’s rigorous product standards.

• Decitabine Enhances Anti–PD-1 Efficacy via CD8+ Progenitor T

  2026-04-22

  This study demonstrates that low-dose Decitabine priming potentiates anti–PD-1 immunotherapy by promoting the expansion and functional capacity of CD8+ progenitor exhausted T cells within tumor models. These findings provide mechanistic insight into how epigenetic modulation can overcome limitations of immune checkpoint blockade and inform future combination strategies in cancer epigenetics.

10228 records 1/682 page Next 12345 下5页 Last page